Author

J. Poissy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Traversier· 2 shared B. Lina· 2 shared B. Padey· 2 shared M. Rosa-Calatrava· 2 shared O. Terrier· 2 shared T. Julien· 2 shared A. Gaymard· 1 shared A. Pizzorno· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Traversier

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia

A. Pizzorno, B. Padey, T. Julien, S. Trouillet-Assant, A. Traversier, E. Errazuriz-Cerda, J. Fouret, J. Dubois, A. Gaymard, X. Lescure, V. Duliere, P. Brun, S. Constant, J. Poissy, B. Lina, , M. Rosa-Calatrava

The paper characterizes SARS-CoV-2 infection in nasal and bronchial airway epithelial models and evaluates the antiviral efficacy of remdesivir and its combination with diltiazem.

bioRxiv · Mar 31, 2020Microbiology

Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures

M. A. Pizzorno, O. Terrier, C. Nicolas de Lamballerie, T. Julien, B. Padey, A. Traversier, M. Roche, M.-E. Hamelin, C. Rheaume, S. Croze, V. Escuret, J. Poissy, B. Lina, C. Legras-Lachuer, J. Textoris, , M. Rosa-Calatrava

This paper identifies 35 FDA-approved drugs with antiviral potential against influenza using transcriptomic signatures, validates 31 in vitro, and highlights diltiazem as a promising candidate for Phase II clinical trials.

bioRxiv · Aug 27, 2018Microbiology